Biosimilar of analogue of insulin glargin: proven safety, effectiveness, interchangeability

Abstract

Diabetes mellitus (DM) is a global medical and social problem, its prevalence is steadily increasing throughout the world. The significance of DM is due to early disability and high mortality, primarily from macro- and microvascular complications of diabetes mellitus. Adequate therapy and its timely intensification in order to achieve an optimal individual level of glycemic control is an important aspect in this regard. Insulin therapy is indicated for all patients with type 1 diabetes mellitus. In type 2 diabetes the appointment of basal insulin is necessary if it is impossible to adequately control glycemia with oral drugs. Treatment of diabetes all over the world and in our country requires significant healthcare costs. The problem of reducing the cost of drug therapy in all countries of the world is currently being solved by the admission to the market of biosimilar drugs (biosimilars). A biosimilar (biosimilar) medicinal product (biosimilar, biosimilar) is a biological product similar in terms of quality, efficacy and safety to a reference biological medicinal product in the same dosage form and having an identical route of administration. Insulin glargine is one of the commonly used drugs in clinical practice and is of interest for reproduction. Biosimilar currently registered. This is a biosimilar of domestic production of insulin glargine with proven bio- and therapeutic equivalence, immune safety, good tolerance, recognized as interchangeable with the original insulin glargine. Indications and contraindications for use can be extrapolated to biosimilar without fear of reducing efficacy and the development of adverse events.